|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM37008618X |
| 003 |
DE-627 |
| 005 |
20240524232531.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240324s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202311803
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1417.xml
|
| 035 |
|
|
|a (DE-627)NLM37008618X
|
| 035 |
|
|
|a (NLM)38519052
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhao, Ya
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Neutrophil Membrane-Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 24.05.2024
|
| 500 |
|
|
|a Date Revised 24.05.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Neuroinflammation has emerged as a major concern in ischemic stroke therapy because it exacebates neurological dysfunction and suppresses neurological recovery after ischemia/reperfusion. Fingolimod hydrochloride (FTY720) is an FDA-approved anti-inflammatory drug which exhibits potential neuroprotective effects in ischemic brain parenchyma. However, delivering a sufficient amount of FTY720 through the blood-brain barrier into brain lesions without inducing severe cardiovascular side effects remains challenging. Here, a neutrophil membrane-camouflaged polyprodrug nanomedicine that can migrate into ischemic brain tissues and in situ release FTY720 in response to elevated levels of reactive oxygen species. This nanomedicine delivers 15.2-fold more FTY720 into the ischemic brain and significantly reduces the risk of cardiotoxicity and infection compared with intravenously administered free drug. In addition, single-cell RNA-sequencing analysis identifies that the nanomedicine attenuates poststroke inflammation by reprogramming microglia toward anti-inflammatory phenotypes, which is realized via modulating Cebpb-regulated activation of NLRP3 inflammasomes and secretion of CXCL2 chemokine. This study offers new insights into the design and fabrication of polyprodrug nanomedicines for effective suppression of inflammation in ischemic stroke therapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a anti‐inflammation
|
| 650 |
|
4 |
|a blood–brain barrier
|
| 650 |
|
4 |
|a ischemic stroke
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
4 |
|a polyprodrug
|
| 650 |
|
4 |
|a scRNA‐seq
|
| 650 |
|
7 |
|a Fingolimod Hydrochloride
|2 NLM
|
| 650 |
|
7 |
|a G926EC510T
|2 NLM
|
| 650 |
|
7 |
|a Prodrugs
|2 NLM
|
| 650 |
|
7 |
|a NLR Family, Pyrin Domain-Containing 3 Protein
|2 NLM
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
| 650 |
|
7 |
|a Reactive Oxygen Species
|2 NLM
|
| 650 |
|
7 |
|a Neuroprotective Agents
|2 NLM
|
| 700 |
1 |
|
|a Li, Qian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Niu, Jingyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Erliang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Chenchen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Jian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Xue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Lihua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rao, Lang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Kuikun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 21 vom: 03. Mai, Seite e2311803
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:21
|g day:03
|g month:05
|g pages:e2311803
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202311803
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 21
|b 03
|c 05
|h e2311803
|